The reference data below covers CytoMed Therapeutics's Net Income - from calculation methodology to the most recent figure. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors. Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Net Income
=
(Rev + Gain)
-
(Exp + Loss)
=
-1.84 M
CytoMed Therapeutics's Net Income is presented here as reference data based on the most recent year, quarter, or monthly disclosures available to us and is not a recommendation.
Analyzing CytoMed Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing CytoMed Therapeutics's current valuation and future prospects.
Latest CytoMed Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of CytoMed Therapeutics Limited over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in CytoMed Therapeutics financial statement analysis. It represents the amount of money remaining after all of CytoMed Therapeutics Limited operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is CytoMed Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytoMed Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Sound financial modeling for CytoMed Therapeutics requires a clear understanding of how CytoMed Therapeutics' accounts, including Net Income, are correlated. Because CytoMed Therapeutics' income statement, balance sheet, and cash flow items are all interconnected, a correlation-based approach to analysis is more effective than examining each statement independently.
The trajectory for Accumulated Other Comprehensive Income suggests it is on track to increase significantly this cycle. The previous fiscal year placed Accumulated Other Comprehensive Income at 13,328.1.
CytoMed Therapeutics Limited has a reported Net Income of -1.84 Million. This reading is 100.54% below the Biotechnology sector and 102.63% below the Health Care industry. Against all United States stocks, CytoMed Therapeutics's net income is 100.32% lower than average.
Fundamental Drivers Relationships
Multiples-driven valuation compares CytoMed Therapeutics across sector performance standards. You can analyze the relationship between different fundamental ratios across CytoMed Therapeutics competition to find correlations between indicators driving CytoMed Therapeutics's intrinsic value. More Info.
CytoMed Therapeutics Limited leads all stocks for net income relative to top peers. It also leads all stocks for return on asset relative to top peers . Currently, Net Loss is projected to decrease significantly based on multi-year reporting trends. Year-ago financials show CytoMed Therapeutics with Net Loss of -1.69 Million. Comparative earnings metrics contextualize CytoMed Therapeutics.
Net Income Peer Comparison
Stock peer comparison using Net Income is a reliable method for evaluating CytoMed Therapeutics against comparable stocks. Investors use CytoMed Therapeutics' Net Income relative to peers to identify whether the stock is attractively or expensively valued.
CytoMed Therapeutics is currently under evaluation for net income relative to top peers.
CytoMed Therapeutics reports annual revenue of 52.01 K, ROE of -42.33%, an operating margin of -4.52%. A closer look at CytoMed Therapeutics highlights capital structure dynamics and profitability sustainability. Cash reserves enhance macroeconomic adaptability. For this reporting period, CytoMed Therapeutics reflects revenue of 52.01 K, EPS loss of 0.25, negative operating margin of 4.52%.
Unless otherwise specified, data for CytoMed Therapeutics Limited is compiled from periodic company reporting and market reference feeds and standardized for comparability. Updates may occur throughout the day. Financial statement fields are presented under issuer-reported GAAP or IFRS accounting conventions.